Establishment Labs turns profitable, raises 2026 outlook
Medical technology company projects 25% revenue growth after fourth-quarter adjusted EBITDA swings to positive
Establishment Labs Holdings swung to profitability in the fourth quarter of 2025 and delivered a stronger-than-expected outlook for this year, marking a turning point for the Costa Rican medical technology company as it expands its global presence in cosmetic and reconstructive surgery.
The company reported revenue of $64.6 million for the quarter, a 45.2% increase from the same period a year earlier and beating analyst estimates by 23.6%. Adjusted EBITDA turned positive at $5.5 million, compared with a loss of $13.1 million in the year-ago quarter, according to regulatory filings.
The loss per share narrowed to 9 cents, significantly better than the 22-cent loss analysts had expected. Despite the earnings beat, shares initially fell in pre-market trading on February 24, suggesting some investors had anticipated an even stronger performance.
Establishment Labs raised its guidance for fiscal year 2026, projecting revenue of $264 million to $266 million, representing growth of 25 to 26% over 2025. That outlook exceeded the analyst consensus of $263 million, according to MarketBeat data. The company also said it expects 2027 revenue growth of at least 25%.
Perhaps most significantly for investors, Establishment Labs indicated it anticipates generating its first quarter of positive cash flow in 2026, a milestone that would mark the company's transition from a growth-stage business to one that can self-fund its expansion.
Establishment Labs, based in Alajuela, Costa Rica, manufactures and markets the Motiva brand of breast implants and other medical devices for cosmetic and reconstructive plastic surgery. The company has been gaining market share in the global medical aesthetics market, which has seen robust demand as consumers resume elective procedures following the disruptions of the pandemic years.
Analysts remain broadly positive on the stock heading into the earnings announcement. The consensus rating stands at "Buy," with eight analysts recommending purchase—two at "Strong Buy" and six at "Buy"—and just one at "Hold," according to market data. The average price target is $83.25, suggesting potential upside from current levels.
The company's turnaround from losses to profitability represents a significant validation of its strategy. Establishment Labs has invested heavily in research and development, marketing, and international expansion, particularly in European and Latin American markets. The positive adjusted EBITDA in the fourth quarter suggests those investments are beginning to yield returns at scale.
The medical aesthetics industry has proven resilient despite economic uncertainties, as consumers prioritize spending on appearance and wellness even during tighter financial conditions. Establishment Labs' Motiva implants have gained traction due to their proprietary technology and positioning as a premium product in a market that has faced quality and safety concerns from competitors in recent years.
Looking ahead, the company's ability to sustain the growth momentum it demonstrated in the fourth quarter will be closely watched by investors. The 25% growth projection for 2027, while ambitious, suggests management sees continued expansion opportunities in both established and emerging markets.
Establishment Labs' transition to profitability and positive cash flow could also position the company for potential strategic partnerships or acquisitions in the consolidating medical aesthetics space, where larger players have been looking to add innovative technologies to their portfolios.